SCIENTIFIC PROGRAMME Saturday, 10 May 2025
007
Increased QTc interval after lisdexamfetamine administration in a patient with an ADHD and Suspected Postural Orthostatic Tachycardia Syndrome
004
USAbility evaluation of an innovative device technology for individualised dosing of oral solid medicines Stina Wigren, Sweden A. Marmaras, A. Larusson Evaluation of a collaborative nurse-physician model for the follow-up of children and ado- lescents during ADHD-medication Ann Christin Andersen, Norway S. Tennfjord, A. Dyb, I. Ølstørn, E. Engeset, I. Berge, J. Lyngstad, L. Reindal Effects of pharmacological and non-pharma- cological interventions for ADHD on emotion dysregulation: Systematic review and meta- analysis Alessio Bellato, United Kingdom L. Marzulli, A. Soler-Gutierrez, G. Sesso, V. Parlatini, S. Cortese Concordance of treatment recommendations for ADHD patients between TDApp and clinical practice guidelines: A hierarchical clustering
Laura Moody, United Kingdom H. Alizai, R. Kaur, M. Mohamad
005
008
Substance use disorder in adults with ADHD: Clinical correlates and treatment response Camilla Perotti, Italy L. Rolle, G. Di Salvo, G. Maina A randomized, open-label, multiple-dose, two-way study to evaluate bioavailability of clonidine HCl ER oral suspension compared to clonidine HCl ER tablets Jim Potenziano, USA E. Rafla, M. Witkovic, J. Horng, J. Grieco Economic evaluation of Dyanavel XR for the treatment of ADHD in US motor vehicle drivers Jim Potenziano, USA J. Cooper, J. Schneider, D. Fam Post hoc analysis of laboratory classroom data for PRC-063 (methylphenidate hydrochloride controlled-release capsules) by gender in adults and children with ADHD Jodan Ratz, Canada A. Childress, G. Donnelly, I. Maharaj Post hoc analysis of clinical data for PRC-063 (methylphenidate hydrochloride controlled- release capsules) by gender in adults, adoles- cents and children with ADHD Jodan Ratz, Canada L. Klassen, G. Donnelly, I. Maharaj, S. Cordeiro Matos
009
006
010
007
011
analysis with dendrograms Xavier Castells Cervelló, Spain
E. Baykova, Ò. Raya, D. Ramírez, C. Lombardía, R. Cunill, D. Losada, T. Falkenhain, D. Serrano, B. López Effects of longer-term stimulant use on heart rate variability, electrodermal activity and objective motor activity in children and ado- lescents with ADHD Aldo Alberto Conti, United Kingdom N. Bozhilova, F. Fiori, L. Johansson, B. Carter, D. Stringer, I. Eraydin, R. Marhenke, P. Santosh, S. Cortese, K. Rubia Differential effects of a single dose of lis- dexamfetamine and guanfacine on cognitive function in children with ADHD Sahid El Masri, Germany K. Rubia Blood pressure trends and variability in chil- dren with ADHD and/or ADHD treated with multi-layer release methylphenidate (MLR- MPH) or lisdexamfetamine (LDX) Natalie Feberova, Canada J. Van Stralen A phase IV, dose optimized, open label, evalu- ation of the effect of multilayer release meth- ylphenidate (MLR-MPH) on sleep in children aged 6-12 with ADHD Natalie Feberova, Canada K. Pullia, S. Wojcik, H. Gray, R. Ilines, J. Van Stralen
008
012
009
P-19 Guided Poster Tour 12:45 – 14:45 Pharmacological treatment II Chair: Jeffrey Newcorn, USA 001
Congress Hall Foyer 2B (2 nd Floor)
010
R emote objective ADHD assessment to monitor treatment effects as part of UK-based virtual healthcare service, ADHD 360 Ragini Sanyal, USA N. Casals, S. Larsson, N. Jennings, A. Lloyd, P. Anderton, M. Hansen A preliminary study: The influence of comorbid psychiatric disorders and psychostimulants on misconducts among incarcerated individuals with ADHD Elssa Toumeh, Canada G. Lorberg, D. Runnalls, A. Greifenberger, K. Fotinos, T. Sternat, I. Epstein, M. Katzman Effectivity of stimulant treatment in adults ADHD Ravian Wettstein, The Netherlands G. Dumont
011
002
003
33
Made with FlippingBook Digital Publishing Software